The Hypoxia Altitude Simulation Test (HAST) is the Gold Standard to evaluate hypoxia in response to altitude and to decide on in-flight requirements for oxygen supplementation. Several equations are available to predict PaO2 in altitude (PaO2alt), but it remains unclear whether their predictive value is equivalent. We aimed to compare the results obtained by the available methods in a population of cystic fibrosis (CF) adults. Methods: Eighty-eight adults (58 healthy controls and 30 CF patients) performed a spirometry followed by an HAST. HAST results were compared with the predicted PaO2alt made by five equations: 1 st : PaO2alt= 0,410 x PaO2ground + 1,7652; 2 nd : PaO2alt= 0,519 x PaO2ground + 11,855 x FEV1 (L) -1,760; 3 rd : PaO2alt= 0,453
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Introduction
The quality of life and life expectancy of patients with cystic fibrosis (CF) have increased substantially during the past years 1 due to medical improvement and preventive initiatives, which currently enable these patients to participate in activities that were not previously feasible, such as tourism. 2 As a result, physicians are increasingly requested to evaluate these patients for their ability to fly safely and the need for oxygen supplementation. 3, 4 Commercial flights expose individuals to a lower atmospheric pressure and consequently to a lower oxygen content, 2 as passenger cabins of commercial aircraft at maximal cruising altitude are pressurized to an altitude equivalent of 2438 m (8000 feet), 1, 3, [5] [6] [7] which is equivalent to breathing 15% oxygen at sea level. [3] [4] [5] [6] [7] [8] [9] [10] This altitude hypobaric hypoxia can be tolerated in healthy individuals, but may cause severe hypoxemia in patients with pulmonary disease. 3,10-14 CF-patients are therefore prone to a substantial and unsafe reduction in the partial arterial oxygen pressure (PaO2) during the flight 1, 12 that may lead to a severe respiratory decompensation. 15 The Aerospace Medical Association 2 and British Thoracic Society (BTS) 4 recommend to perform a hypoxic altitude simulation test (HAST) to assess whether patients need in-flight oxygen supplementation. The HAST is considered the gold standard 11 and it can be done by artificially reducing inspired oxygen to similar levels as those experienced at 2438 m (8000 feet) for 20 min by either reducing the fraction of inspired oxygen to 15% 1, 4, 7, 11 or by reducing atmospheric pressure to 565 Torr (75 kPa) in a hypobaric chamber. 4, 11 The normobaric HAST is usually the preferred technique, as it is more accessible and inexpensive than the HAST performed in a hypobaric chamber. The expected PaO2 (PaO2HAST) is then determined from measurements of arterial blood gases (ABG). 11 A subject is judged to require in-flight oxygen supplementation if the PaO2HAST falls below 50 mmHg, although this arbitrary cut-off value has little supporting evidence. 4 Security cut-offs have been proposed that can be used when HAST is not available. In the case of CF, patients with FEV1 > 50% or PaO2ground > 60 mmHg can safely be allowed to travel without oxygen supplementation. 3, 12 In addition, several investigators have developed predictive equations that estimate PaO2 at altitude (PaO2alt) using measurements made at sea level. 6, 11, 14, 16, 17 The BTS guidelines refers to four of them, but they have been derived almost exclusively from patients with chronic obstructive pulmonary disease who undergone a HAST. 4 Only one study, performed by Kamin et al. 17 (in our study referred as 5 th equation ) testing 12 adults with CF with mild to moderate respiratory insufficiency (mean PaO2: 79 mmHg) proposed one equation to predict the expected hypoxemia for flights of up to 3,5 hours in duration. 17 The aim of this study was to compare HAST results with those predicted by the available equations in a population of adults diagnosed with CF in order to evaluate their performance in distinguishing those who need in-flight oxygen supplementation from those who do not. 
Materials and Methods
CF
Results
Out of the 88 randomly selected adults, all were caucasians and the majority were women (52.27%) with a median age of 22 years old. Between CF-patients and the healthy controls, there was a significant difference in weight, height and body mass index (BMI) (p<0.001), with CF-patients being thinner and shorter. In the control group, 18.96% were former smokers and 12.06% current smokers, while all of the CF-patients were non-smoker. No statistically significant difference was found for age and gender.
Clinical characteristics of the sample studied are summarized in Table 1 .
We found significant differences when comparing the recorded functional respiratory values: CF-patients had lower FVC, FEV1 and FEV1/FVC (p< 0.001). CFpatients had also lower PaO2ground, SatO2ground, PaO2HALT, SatO2HAST and lower minimal oxygen saturation (SpO2min) measured during HAST (p<0.001). Respiratory functional results are summarized in Table 2 .
None of the healthy controls reached a PaO2HAST below 50 mmHg, while 11 (36.7%) of the CF-patients had lower values, with 42.7 mmHg being the lowest founded value - Table 3 .
When CF-patients were divided by PaO2HAST (below or above 50 mmHg), a significant difference was found for weight (p=0.002), BMI (p<0.002), FVC, FEV1 (p<0.001), FEV1/FVC (p=0.003), PaO2ground (p=0.008) and SatO2ground (p<0.007), with patients with PaO2HAST <50 mmHg having lower values. No difference was found for age (p=1), gender (p=0.466) or height (p=0.219) between CF-patients.
Adjustment between groups
As the healthy controls and CF-patients have significant differences, we performed an adjustment for tobacco usage, BMI and height. All smokers and former smokers were excluded. Out of the 70 non-smoker adults (40 healthy controls and 30 CF-patients), the majority were women (54.28%) with a median age of 22 years old. Between CFpatients and the healthy controls, as expected, there was a significant difference in weight (p< 0.001), height (p=0.003) and BMI (p< 0.001). No statistically significant difference was found for age (p= 0.092) and gender (p= 1).
Significant differences were found when analyzing functional respiratory values: CF-patients had lower FVC, FEV1 and FEV1/FVC (p< 0.001). CF-patients had also lower PaO2ground, SatO2ground, PaO2HAST, SatO2HAST (p< 0.001) and a lower SpO2min measured during HAST (p< 0.001).
With all five equations, the mean predicted PaO2alt had a significant difference between healthy controls and CF-patients (p<0.001). When the five equations were compared to each other, the mean predicted PaO2alt had also a significant difference (p≤0.005), but when a cut-off of 50 mmHg was used, no difference was found (p=0,51).
To prevent a confounding effect by BMI and height, we used a correction based on multiple linear regression. This method allows to take into consideration the variability associated with each factor. A significant difference was still found between the groups on FVC, FEV1 and FEV1/FVC, PaO2ground, SatO2ground, PaO2HAST, SatO2HAST, SpO2min and predicted PaO2alt by the five equations (p< 0.001).
Equation comparison
Healthy adults and CF-patients: When the values of PaO2alt in the healthy controls and CF-patients were compared, a significant difference was found in all five equations (p< 0.001). The lowest predicted PaO2alt was found with the 5 th equation, on the CF-patient group (34.2 mmHg) - Table 3 . This value was lower than the respective PaO2HAST found. When a cut-off of 50 mmHg for PaO2alt was used, none of the control had a predicted PaO2alt < 50 mmHg. We used a non-parametrical approach for all variables when CF-patients were divided by PaO2HAST (below or above 50 mmHg), because the groups became smaller. In this case, a significant difference was found for weight (p=0.002), BMI (p<0.002), FVC, FEV1 (p<0.001), FEV1/FVC (p=0.003), PaO2ground (p=0.008) and SatO2ground (p<0.007). Patients with PaO2HAST <50 mmHg had the lowest values. No difference was found on age (p=1), gender (p=0.466) or height (p=0.219) between CF-patients.
Using this cut-off, there were no evidences of significant differences between the case distribution among the equations (p=0.369). However, when we compare with the case distribution based on the results from the HAST test, some CF-patients were misclassified - Table 4 and Table 5 .
We found no statistically significant difference on the sensibility of each equation (63.64%) and the specificity was 63.16% (1 st equation), 94.74% (2 nd and 3 rd ), 89.47% (4 th ) and 74.68% (5 th ). The positive predictive value was 50% (1 st equation), 87.5% (2 nd and 3 rd ), 77.78% (4 th ) and 58.33% (5 th ). The negative predictive value was 75% (1 st equation), 81.82% (2 nd and 3 rd ), 80.95% (4 th ) and 77.78% (5 th ).
In order to compare the performance of the five equations with the cut-off of 50 mmHg, ROC curves were performed (Figure 1) . The 3 rd equation had the best performance with an AUC of 88.04%.
Prediction of in-flight oxygen need in CF-patients
To test whether the requirement for in-flight oxygen supplementation could be predicted by PaO2ground and/or by FEV1 (in Liters and predicted percentage), we analyzed the CF-patients with PaO2HAST < 50 mmHg (n=11). Of this sub-group eight (72.73%) had FEV1 < 50%, six (54.55%) had PaO2ground < 70 mmHg, two of which had < 65 mmHg.
A relation between FEV1(in liters)/ PaO2HAST, FEV1(%)/ PaO2HAST and PaO2ground/
PaO2HAST was found (p< 0.001) - Figure 2 .
Out of the patients that required in-flight oxygen supplementation, 10 had FEV1 < 2 Liters, one FEV1 > 3 Liters, all had FEV1 < 60 % of the predicted value and PaO2ground > 60 mmHg, with one patient having PaO2ground > 90 mmHg.
Discussion
Guidelines refer to predictive equations of altitude hypoxia as either a screening tool for recommending a HAST or as a replacement when this test is not available, 11 but the accuracy and predictive value of the available equation in relation to the HAST Gold Standard has not been previously evaluated in CF patients in comparison to healthy individuals. In our sample, we found a significant difference between healthy and CFpatients even when adjusted for tobacco usage, BMI or height. In our sample, 11 CFpatients and none of the healthy controls reached a PaO2HAST below 50 mmHg. Patients who needed in-flight oxygen supplementation were thinner, had lower FVC, FEV1, FEV1/FVC, PaO2ground and SatO2ground than those who did not.
While the 3 rd equation performed better than the other four, when compared to HAST results, none was able to correctly identify CF-patients that required in-flight oxygen supplementation. In a previous study, Martin et al. 5 tested the prediction of the first four equations in 15 adults with CF and concluded that the four equations overestimated the need of in-flight oxygen. In our sample, only the first and fifth equations overestimated the HAST results. While overestimation will lead to unnecessary prescription of oxygen in flight with no clinical risk but increasing flight cost, possibly making the trip unfeasible, the opposite could lead a significant clinical risk. Therefore, we do not recommend to use these equations as screening tools or substitute of HAST.
According to some literature, 3, 12 CF-patients with FEV1 > 50% or PaO2ground > 60 mmHg can safely travel without oxygen supplementation. Therefore, this recommendation would exempt the performance of HAST in these patients. In fact, in our sample, FEV1 and PaO2ground correlated with HAST results, with FEV1 in predicted percentage being the most accurate. However, contrary to the recommendations described above, all patients that needed in-flight oxygen had a FEV1 < 60% while no other cut-off on FEV1 in Liters or PaO2ground was able to correctly predict those who reached PaO2HAST below 50 mmHg. We do not recommend to use the previous values of FEV1 (> 50% of the predicted value) or PaO2ground (> 60 mmHg) as, in our sample, tree patients with FEV1 > 50% and all 11 patients that needed in-flight oxygen had PaO2ground > 60 mmHg.
We found a large variability between the results given by HAST and the values predicted by the different equations studied. The third equation produced predictions closer to the results observed by HAST, but given the individual difference found, the authors recommend to, whenever possible, perform a HAST to analyze commercial air flights risks. 
